Shilpa Medicare and Gate2brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy
Shilpa Medicare has entered a strategic equity partnership with Gate2Brain to develop a novel therapy for pediatric brain cancers. The collaboration focuses on using a proprietary peptide shuttle to improve drug delivery across the blood-brain barrier.
Why it matters
This partnership combines specialized biotechnology with manufacturing scale to address high-mortality pediatric oncology markets.
Shilpa Biocare Pvt Ltd, a subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain’s lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain’s proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28.
The article is a straightforward business announcement regarding a corporate partnership and medical research.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in